Minimal Residual Disease Testing for the Early Detection of Cancer Recurrence in Resectable Stage II-IV Colorectal Cancer Patients
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This clinical trial compares minimal residual disease (MRD) testing with the Haystack blood test (assay) to the Signatera® assay for the early detection of the cancer returning (cancer recurrence) in patients with stage II-IV colorectal cancer (CRC) that can be removed by surgery (resectable). MRD testing looks for evidence of remaining tumor following treatment that is only apparent using highly sensitive techniques. There are few effective tools available outside of imaging to identify CRC patients with MRD who may be at the highest risk for cancer recurrence after surgery. Early detection of CRC recurrence after surgery is important, as it may increase the chance of curative (ability to cure) outcomes for patients with cancer recurrence. Currently, the Signatera assay is used to monitor whether CRC recurs after surgery, however it is not a very sensitive test. Early work with the Haystack assay suggests it may be more sensitive than the Signatera assay, which may be more effective for the early detection of cancer recurrence in patients with resectable stage II-IV CRC.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Rozpoznanie raka jelita grubego w stadiu II, III lub IV
- •Pacjent przed operacją lub po operacyjnym usunięciu guza (z zamiarem całkowitego leczenia)
- •Zgoda na pobieranie krwi co 3 miesiące przez 2 lata, a następnie co 6 miesięcy przez kolejne 3 lata
- •Dostępne próbki tkanki guza do badania
- •Gotowość do uczestnictwa w badaniu z oboma testami krwi
✗ Disqualifies
- •Brak możliwości bezpiecznego pobierania próbek krwi
- •Nieusunięte przerzuty nowotworowe w ciele
- •Brak możliwości wyrażenia świadomej zgody
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 12, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (13)
CTCA at Western Regional Medical Center
Goodyear, United States
City of Hope Corona
Corona, United States
City of Hope Comprehensive Cancer Center
Duarte, United States
City of Hope Seacliff
Huntington Beach, United States
City of Hope at Irvine Lennar
Irvine, United States
City of Hope Antelope Valley
Lancaster, United States
City of Hope at Long Beach Elm
Long Beach, United States
City of Hope at Newport Beach Fashion Island
Newport Beach, United States
City of Hope South Pasadena
South Pasadena, United States
City of Hope South Bay
Torrance, United States
City of Hope Upland
Upland, United States
City of Hope Atlanta Cancer Center
Newnan, United States
City of Hope at Chicago
Zion, United States
Trial contact
Marwan G. Fakih
Marwan G. Fakih
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/13/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.